Elevara Appoints Scientific Advisory Board

Three renowned experts in rheumatology and immunology

London, UK – 17 November 2026 – Elevara Medicines ("Elevara"), a clinical-stage biotech developing therapies for rheumatoid arthritis ("RA") and other chronic inflammatory diseases, today announced the creation of a Scientific Advisory Board (SAB) that comprises three internationally renowned experts in rheumatology and immunology.

Professor Maya Buch is a highly distinguished rheumatologist who serves as a Professor of Rheumatology and Director of Experimental Medicine at the Centre for Musculoskeletal Research at the University of Manchester. Concurrently, she holds the positions of Honorary Consultant Rheumatologist at the Manchester University NHS Foundation Trust and National Institute for Health and Care Research (NIHR) Senior Investigator. Her leading research program focuses heavily on clinical and translational medicine, specifically targeted therapies and personalized medicine within rheumatoid arthritis (RA), ranging from early diagnosis to difficult-to-treat refractory disease

Professor John Isaacs is the Professor of Clinical Rheumatology and Director of Therapeutics at Newcastle University, concurrently serving as an Honorary Consultant Rheumatologist and Director of Research at the Newcastle upon Tyne Hospitals NHS Foundation Trust. Globally recognized as a pioneer in translational rheumatoid arthritis (RA) research, his key scientific interests centre on novel immunotherapies, precision therapeutics, and therapeutic tolerance induction.

Professor Georg Schett is the Vice President for Research at the Friedrich-Alexander-Universität. Erlangen-Nürnberg (FAU) and the Director of the Department of Medicine 3 - Rheumatology & Immunology at Universitätsklinikum, Erlangen. His pioneering research focuses on the molecular and cellular pathogenesis of autoimmune diseases, the mechanisms behind the resolution of inflammation, and the interface of the skeletal and immune systems (the "IMMUNOBONE" field). Globally, he is highly celebrated for spearheading the groundbreaking use of chimeric antigen receptor (CAR) T-cell therapy to reset the immune system in patients with severe, refractory autoimmune conditions like lupus, scleroderma, and myositis.

Commenting on the creation of the Senior Advisory Board, **Mai Britt Zocca, CEO,** said: *"We have been extremely fortunate to attract three leading experts in rheumatology and immunology, Professors Buch, Isaacs and Schett, and we thank them for joining Elevara's SAB. With the help of their advice and clinical expertise, I believe there is a great opportunity to improve the lives of people with rheumatoid arthritis."*

Professor Dominque Baeten, CMO added*: "At Elevara, we are aiming to transform RA treatment by targeting stromal pathways of disease as an add on approach on top of standard of care. The approach we are taking is completely different to current treatment regimes, where patients that don't achieve remission end up cycling through many different treatments. Having such a prestigious group of experts on our SAB is a real validation of our approach and will be a huge help in future as we expand our clinical programs."*

Elevara's lead candidate, ELV001, is a first-in-class oral CDK4/6 inhibitor that selectively targets fibroblast-like synoviocytes, a key driver of RA pathology, without affecting the immune system. ELV001, is in a Phase 2b START-SYNERGY trial being tested in up to 220 patients with an inadequate response to methotrexate and TNF inhibitors. The clinical trial is looking at

the change in DAS28-CRP at week 12, a validated measure of RA disease activity. Elevara is backed by investors, Forbion, Sofinnova Partners, Monograph Capital and Weatherden.

-Ends-

Pictures of the SAB



Professor Maya Buch



Professor John Isaacs



Professor Georg Schett

Notes to Editors

Elevara Medicines

Elevara is a clinical-stage company developing new therapeutics to treat rheumatoid arthritis (RA) and other chronic inflammatory conditions. The company's lead program, ELV001, is a potent, selective and well-differentiated first-in-class oral CDK4/6 inhibitor that is currently recruiting patients in its Phase 2b START-SYNERGY clinical trial.

The ELV001 programme is being positioned as an add-on oral therapy for RA patients with an incomplete response to a TNF inhibitor, with the potential to prevent cycling between multiple immunosuppressive therapies.

The company was co-founded by Weatherden, a UK based clinical advisory group, with operational support and seed capital from Monograph Capital. Elevara raised a $70 million in a Series A in October 2025. Its investors include Sofinnova Partners, Forbion and Monograph Capital. For more information, visit www.elevara.com.

For more information, please contact:

Elevara Medicines
Mai-Britt Zocca, CEO
Dominique Baeten, CMO
info@elevara.com

Vigo Consulting (media)
Melanie Toyne-Sewell / Rozi Morris
Elevara@vigoconsulting.com
+44 7890 022 814